It may not be the catchiest of names, but AstraZeneca drug MEDI4736 was revealed on Wednesday night as a "new great white hope" in the fight against cancer as it took centre stage in the British company's battle against Pfizer's planned £63bn takeover.
Here is some excellent advice from an old hand to the directors of AstraZeneca should Pfizer, as expected, get serious about bidding and increase its current £48-a-share offer: don't be swayed by the views of investment bankers chasing success fees; don't judge bid premiums based on a two- to three-year view; and remember you have responsibilities beyond price.
Pfizer has said it will keep its promises about keeping high-skill jobs and manufacturing in Britain before the US company's boss faces his first grilling by MPs on the proposed takeover of AstraZeneca.
Speculation is growing that Pfizer, the maker of Viagra, is preparing to raise its takeover offer for AstraZeneca, Britain's second-largest drugmaker, to more than £63bn.
Let's get this right.
AstraZeneca boss Pascal Soriot fired a warning shot across the bows of bigger US rival Pfizer, a potential suitor, as he insisted that the British drugmaker's strategy was working and highlighted progress with new cancer drugs.
New concerns about the security of jobs in the pharmaceutical sector will be raised this week amid speculation that Pfizer of the US has been in takeover talks with its struggling rival, the Anglo-Swedish group AstraZeneca.
AstraZeneca has continued its recent acquisition burst with the purchase of a UK biotech business.
Chinese police have arrested a second western businessman in connection with an investigation into alleged bribery of doctors by drug companies.
AstraZeneca has suffered another drug trial setback.
AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector.
AstraZeneca received a much-needed boost when its blood-thinning drug, Brilinta, a potential blockbuster, was approved by the US health regulator for wider use.
AstraZeneca, which fended off a £69bn takeover attempt from American rival Pfizer almost a year ago, unveiled a better-than-expected set of quarterly results and strengthened its cancer portfolio with two new deals.